Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-483 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9186.026 | 1.1072 | 1.4413 | 0.5108 | |
| BT-483 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9186.026 | 1.0681 | 1.2754 | 0.5108 | |
| BT-483 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9186.026 | 1.0061 | 1.0239 | 0.5108 | |
| BT-483 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9186.026 | 1.0862 | 1.3515 | 0.5108 | |
| BT-483 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9186.026 | 1.0085 | 1.0333 | 0.5108 | |
| BT-483 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9186.026 | 1.0297 | 1.1177 | 0.5108 | |
| BT-483 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9186.026 | 0.9406 | 0.7741 | 0.5108 | |
| BT-549 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 10261.026 | 1.0222 | 1.0177 | 2.4866 | |
| BT-549 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 10261.026 | 0.9943 | 0.9954 | 2.4866 | |
| BT-549 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 10261.026 | 1.0120 | 1.0096 | 2.4866 | |
| BT-549 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 10261.026 | 1.0169 | 1.0136 | 2.4866 | |
| BT-549 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 10261.026 | 1.0042 | 1.0034 | 2.4866 | |
| BT-549 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 10261.026 | 1.0301 | 1.0240 | 2.4866 | |
| BT-549 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.288 | uM | 10261.026 | 1.0824 | 1.0647 | 2.4866 | |
| BT-549 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 1.44 | uM | 10261.026 | 1.0210 | 1.0168 | 2.4866 | |
| BT-549 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 7.2 | uM | 10261.026 | 0.8062 | 0.8340 | 2.4866 | |
| CAMA-1 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9210.026 | 1.0456 | 1.1004 | 0.9102 | |
| CAMA-1 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9210.026 | 1.0176 | 1.0387 | 0.9102 | |
| CAMA-1 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9210.026 | 1.0352 | 1.0776 | 0.9102 | |
| CAMA-1 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9210.026 | 1.0231 | 1.0509 | 0.9102 | |
| CAMA-1 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9210.026 | 1.0433 | 1.0953 | 0.9102 | |
| CAMA-1 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9210.026 | 1.0244 | 1.0537 | 0.9102 | |
| CAMA-1 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9210.026 | 1.0364 | 1.0802 | 0.9102 | |
| CAMA-1 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9210.026 | 1.0528 | 1.1163 | 0.9102 | |
| CAMA-1 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9210.026 | 0.9789 | 0.9536 | 0.9102 |